These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2454319)

  • 1. Prostaglandin E1 in infants with critical congenital heart disease.
    Dungan WT
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Jan; 1(1):71-4. PubMed ID: 2454319
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 3. Dilation of the ductus arteriosus by oral prostaglandin E1 derivative in cyanotic congenital heart diseases.
    Matsuura H; Saji T; Yamamoto S; Ishikita T; Aoki Y; Matsuo N
    Am Heart J; 1993 May; 125(5 Pt 1):1453-4. PubMed ID: 8480610
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn.
    Gupta N; Kamlin CO; Cheung M; Stewart M; Patel N
    Arch Dis Child Fetal Neonatal Ed; 2013 Mar; 98(2):F186-8. PubMed ID: 23235993
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostaglandin E1 in newborn infants with ductus-dependent heart diseases. Review of 40 cases].
    Simões LC; Sarachaga IH; Quero M; Casanova M; Cazzaniga M; Villibre D
    Arq Bras Cardiol; 1985 Jul; 45(1):31-6. PubMed ID: 3938651
    [No Abstract]   [Full Text] [Related]  

  • 8. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH
    Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
    Tálosi G; Katona M; Rácz K; Kertész E; Onozó B; Túri S
    J Perinat Med; 2004; 32(4):368-74. PubMed ID: 15346826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of prostaglandins in duct-dependent congenital heart conditions.
    Singh Y; Mikrou P
    Arch Dis Child Educ Pract Ed; 2018 Jun; 103(3):137-140. PubMed ID: 29162633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.
    Freed MD; Heymann MA; Lewis AB; Roehl SL; Kensey RC
    Circulation; 1981 Nov; 64(5):899-905. PubMed ID: 7285305
    [No Abstract]   [Full Text] [Related]  

  • 14. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.
    Kerins DM; Murray R; FitzGerald GA
    Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945
    [No Abstract]   [Full Text] [Related]  

  • 16. Critical pharmacologic management in the emergency department.
    Rosenberg NM; Powell EC; Lennarz WM; Stanley R
    Pediatr Emerg Care; 1998 Oct; 14(5):376-9. PubMed ID: 9814412
    [No Abstract]   [Full Text] [Related]  

  • 17. Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1.
    Gittenberger-de Groot AC; Strengers JL
    Int J Cardiol; 1988 May; 19(2):153-66. PubMed ID: 3372078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of clinical response to prostaglandin E1 in a cyanotic infant with congenital absence of the ductus arteriosus.
    Hamilton WT; Lacina SJ; Bharati S; Lev M; Arcilla RA
    Cathet Cardiovasc Diagn; 1982; 8(3):273-6. PubMed ID: 7201887
    [No Abstract]   [Full Text] [Related]  

  • 19. Care of the infant with ductus-dependent congenital heart disease receiving prostaglandin E1.
    Stachura L
    Issues Compr Pediatr Nurs; 1984; 7(4-5):203-15. PubMed ID: 6569057
    [No Abstract]   [Full Text] [Related]  

  • 20. Supportive and emergency use of prostaglandin in the neonate with congenital heart disease.
    Hussain A; al Khudhairi D
    Middle East J Anaesthesiol; 1993 Feb; 12(1):73-81. PubMed ID: 8316154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.